Condition: Congenital Erythropoietic Porphyria (CEP) · Sponsor: Atlas Molecular Pharma
This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD
This description comes directly from the study's public registry record.
Cristina Garrido · +34 688 849 117 · cgarrido@atlasmolecularpharma.com
Mireia Pujals · +34 688 849 117 · mpujals@atlasmolecularpharma.com
Always discuss trial participation with your own doctor first.
| The Cleveland Clinics | Cleveland, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07024316